Skip to main content
Top
Published in: Clinical Drug Investigation 5/2010

01-05-2010 | Original Research Article

Effects of Oral Contraceptives Containing Ethinylestradiol with Either Drospirenone or Levonorgestrel on Various Parameters Associated with Well-Being in Healthy Women

A Randomized, Single-Blind, Parallel-Group, Multicentre Study

Authors: Sue Kelly, Emyr Davies, Simon Fearns, Carol McKinnon, Dr Rick Carter, Christoph Gerlinger, Andrew Smithers

Published in: Clinical Drug Investigation | Issue 5/2010

Login to get access

Abstract

Background: The combined oral contraceptive Yasmin® (drospirenone 3 mg plus ethinylestradiol 30 μg [DRSP 3 mg/EE 30 μg]) has been shown to be a well tolerated and effective combination that provides high contraceptive reliability and good cycle control. Furthermore, DRSP 3 mg/EE 30 μg has been shown to have a positive effect on premenstrual symptoms and well-being/health-related quality of life, and to improve the skin condition of women with acne. To date, however, there have been relatively few studies that have compared the effects of DRSP 3 mg/EE 30 μg on the general well-being of women with those of other oral contraceptives.
Objectives: To compare the impact of DRSP 3 mg/EE 30 μg with that of levonorgestrel 150 mg/EE 30 μg (LNG 150 μg/EE 30 μg; Microgynon® 30) on various parameters associated with well-being in healthy female subjects.
Methods: This was a randomized, single-blind, parallel-group, multicentre study conducted using 21/7-day regimens of DRSP 3 mg/EE 30 μg and LNG 150 μg/EE 30 μg over seven cycles. Efficacy parameters included: changes in Menstrual Distress Questionnaire (MDQ) normative T scores; the proportion of subjects with acne; and menstrual symptoms. Cycle control and subjective well-being parameters were also assessed.
Results: Treatment with DRSP 3 mg/EE 30 μg had similar beneficial effects on symptoms of water retention and impaired concentration to LNG 150 μg/EE 30 μg, but was significantly better in alleviating negative affect symptoms during the menstrual phase (median difference in MDQ T score −3; p = 0.027; Wilcoxon rank sum test). The proportion of subjects with acne decreased from approximately 55% to approximately 45% in the DRSP 3 mg/EE 30 μg group, but remained static at approximately 60% in the LNG 150 μg/EE 30 μg group. Somatic and psychological symptoms occurred at the greatest intensity and for most subjects during the menstrual phase of the cycle in both groups. Both drugs had similar cycle control parameters with a tendency towards reduced bleeding with continued use. More subjects in the DRSP 3 mg/EE 30 μg group reported improved physical well-being (60% vs 46%; p = 0.035; chi-squared [χ2] test). Emotional well-being was reported improved in 61% and 51% of DRSP 3 mg/EE 30 μg and LNG 150 μg/EE 30 μg users, respectively (p = 0.1190; χ2 test). Adverse events were typical of oral contraceptive use and did not give rise to any safety concerns.
Conclusion: Both products had similar beneficial effects on symptoms of water retention and impaired concentration, but DRSP 3 mg/EE 30 μg was significantly better in alleviating negative affect symptoms during the menstrual phase. The proportion of subjects with acne decreased in the DRSP 3 mg/EE 30 μg group but not in the LNG 150 μg/EE 30 μg group. More subjects in the DRSP 3 mg/EE 30 μg group reported improved physical well-being compared with the LNG 150 μg/EE 30 μg group.
Literature
1.
go back to reference Borgelt-Hansen L. Oral contraceptives: an update on health benefits and risks. J Am Pharm Assoc 2001; 41: 875–86 Borgelt-Hansen L. Oral contraceptives: an update on health benefits and risks. J Am Pharm Assoc 2001; 41: 875–86
2.
go back to reference Gold MA, Johnson LM. Intrauterine devices and adolescents. Curr Opin Obstet Gynecol 2008 Oct; 20(5): 464–9PubMedCrossRef Gold MA, Johnson LM. Intrauterine devices and adolescents. Curr Opin Obstet Gynecol 2008 Oct; 20(5): 464–9PubMedCrossRef
3.
go back to reference Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000; 62(1): 29–38PubMedCrossRef Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000; 62(1): 29–38PubMedCrossRef
4.
go back to reference Foidart JM, Wuttke W, Bouw GM, et al. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care 2000 Jun; 5(2): 124–34PubMedCrossRef Foidart JM, Wuttke W, Bouw GM, et al. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care 2000 Jun; 5(2): 124–34PubMedCrossRef
5.
go back to reference Parsey KS, Pong A. An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception 2000 Feb; 61(2): 105–11PubMedCrossRef Parsey KS, Pong A. An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception 2000 Feb; 61(2): 105–11PubMedCrossRef
6.
go back to reference Huber J, Foidart JM, Wuttke W, et al. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. Eur J Contracept Reprod Health Care 2000 Mar; 5(1): 25–34PubMedCrossRef Huber J, Foidart JM, Wuttke W, et al. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. Eur J Contracept Reprod Health Care 2000 Mar; 5(1): 25–34PubMedCrossRef
7.
go back to reference Borenstein J, Yu HT, Wade S, et al. Effect of an oral contraceptive containing ethinyl estradiol and drospirenone on premenstrual symptomatology and health-related quality of life. J Reprod Med 2003 Feb; 48(2): 79–85PubMed Borenstein J, Yu HT, Wade S, et al. Effect of an oral contraceptive containing ethinyl estradiol and drospirenone on premenstrual symptomatology and health-related quality of life. J Reprod Med 2003 Feb; 48(2): 79–85PubMed
8.
go back to reference Freeman EW, Kroll R, Rapkin A, et al. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Womens Health Gend Based Med 2001 Jul–Aug; 10(6): 561–9PubMedCrossRef Freeman EW, Kroll R, Rapkin A, et al. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Womens Health Gend Based Med 2001 Jul–Aug; 10(6): 561–9PubMedCrossRef
9.
go back to reference Brown C, Ling F, Wan J. A new monophasic oral contraceptive containing drospirenone: effect on premenstrual symptoms. J Reprod Med 2002 Jan; 47(1): 14–22PubMed Brown C, Ling F, Wan J. A new monophasic oral contraceptive containing drospirenone: effect on premenstrual symptoms. J Reprod Med 2002 Jan; 47(1): 14–22PubMed
10.
go back to reference Boschitsch E, Skarabis H, Wuttke W, et al. The acceptability of a novel oral contraceptive containing drospirenone and its effect on well-being. Eur J Contracept Reprod Health Care 2000 Dec; 5Suppl. 3: 34–40PubMed Boschitsch E, Skarabis H, Wuttke W, et al. The acceptability of a novel oral contraceptive containing drospirenone and its effect on well-being. Eur J Contracept Reprod Health Care 2000 Dec; 5Suppl. 3: 34–40PubMed
11.
go back to reference Thorneycroft H, Gollnick H, Schellschmidt I. Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment. Cutis 2004 Aug; 74(2): 123–30PubMed Thorneycroft H, Gollnick H, Schellschmidt I. Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment. Cutis 2004 Aug; 74(2): 123–30PubMed
12.
go back to reference vanVloten WA, vanHaselen CW, van Zuuren EJ, et al. The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis 2002 Apr; 69(4 Suppl.): 2–15PubMed vanVloten WA, vanHaselen CW, van Zuuren EJ, et al. The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis 2002 Apr; 69(4 Suppl.): 2–15PubMed
14.
go back to reference Moos RH. The development of a menstrual distress questionnaire. Psychosom Med 1968 Nov–Dec; 30(6): 853–67PubMed Moos RH. The development of a menstrual distress questionnaire. Psychosom Med 1968 Nov–Dec; 30(6): 853–67PubMed
15.
go back to reference Gerlinger C, Endrikat J, Kallischnigg G, et al. Evaluation of menstrual bleeding patterns: a new proposal for a universal guideline based on the analysis of more than 4500 bleeding diaries. Eur J Contracept Reprod Health Care 2007 Sep; 12(3): 203–11PubMedCrossRef Gerlinger C, Endrikat J, Kallischnigg G, et al. Evaluation of menstrual bleeding patterns: a new proposal for a universal guideline based on the analysis of more than 4500 bleeding diaries. Eur J Contracept Reprod Health Care 2007 Sep; 12(3): 203–11PubMedCrossRef
16.
go back to reference Gerlinger C, Endrikat J, van der Meulen EA, et al. Recommendation for confidence interval and sample size calculation for the Pearl Index. Eur J Contracept Reprod Health Care 2003 Jun; 8(2): 87–92PubMed Gerlinger C, Endrikat J, van der Meulen EA, et al. Recommendation for confidence interval and sample size calculation for the Pearl Index. Eur J Contracept Reprod Health Care 2003 Jun; 8(2): 87–92PubMed
17.
go back to reference Sulak PJ, Scow RD, Preece C, et al. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 2000 Feb; 95(2): 261–6PubMedCrossRef Sulak PJ, Scow RD, Preece C, et al. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 2000 Feb; 95(2): 261–6PubMedCrossRef
18.
go back to reference Sulak PJ, Kuehl TJ, Ortiz M, et al. Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. Am J Obstet Gynecol 2002 Jun; 186(6): 1142–9PubMedCrossRef Sulak PJ, Kuehl TJ, Ortiz M, et al. Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. Am J Obstet Gynecol 2002 Jun; 186(6): 1142–9PubMedCrossRef
19.
go back to reference Muhn P, Fuhrmann U, Fritzemeier KH, et al. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Ann N Y Acad Sci 1995 Jun 12; 761: 311–35PubMedCrossRef Muhn P, Fuhrmann U, Fritzemeier KH, et al. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Ann N Y Acad Sci 1995 Jun 12; 761: 311–35PubMedCrossRef
21.
go back to reference Oranratanaphan S, Taneepanichskul S. A double blind randomized control trial, comparing effect of drospirenone and gestodene to sexual desire and libido. J Med Assoc Thai 2006 Oct; 89Suppl. 4: S17–22PubMed Oranratanaphan S, Taneepanichskul S. A double blind randomized control trial, comparing effect of drospirenone and gestodene to sexual desire and libido. J Med Assoc Thai 2006 Oct; 89Suppl. 4: S17–22PubMed
22.
go back to reference Endrikat J, Jaques MA, Mayerhofer M, et al. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/ 75 micrograms gestodene and 20 micrograms ethinylestradiol/ 150 micrograms desogestrel, with respect to efficacy, cycle control and tolerance. Contraception 1995 Oct; 52(4): 229–35PubMedCrossRef Endrikat J, Jaques MA, Mayerhofer M, et al. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/ 75 micrograms gestodene and 20 micrograms ethinylestradiol/ 150 micrograms desogestrel, with respect to efficacy, cycle control and tolerance. Contraception 1995 Oct; 52(4): 229–35PubMedCrossRef
23.
go back to reference Endrikat J, Muller U, Dusterberg B. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/ 75 micrograms gestodene and 30 micrograms ethinylestradiol/ 75 micrograms gestodene, with respect to efficacy, cycle control, and tolerance. Contraception 1997 Mar; 55(3): 131–7PubMedCrossRef Endrikat J, Muller U, Dusterberg B. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/ 75 micrograms gestodene and 30 micrograms ethinylestradiol/ 75 micrograms gestodene, with respect to efficacy, cycle control, and tolerance. Contraception 1997 Mar; 55(3): 131–7PubMedCrossRef
24.
go back to reference Endrikat J, Dusterberg B, Ruebig A, et al. Comparison of efficacy, cycle control, and tolerability of two low-dose oral contraceptives in a multicenter clinical study. Contraception 1999 Nov; 60(5): 269–74PubMedCrossRef Endrikat J, Dusterberg B, Ruebig A, et al. Comparison of efficacy, cycle control, and tolerability of two low-dose oral contraceptives in a multicenter clinical study. Contraception 1999 Nov; 60(5): 269–74PubMedCrossRef
25.
go back to reference Archer DF, Maheux R, DelConte A, et al. Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 microg levonorgestrel and 20 microg ethinyl estradiol (Alesse). North American Levonorgestrel Study Group (NALSG). Am J Obstet Gynecol 1999 Nov; 181 (5 Pt 2): 39–44PubMedCrossRef Archer DF, Maheux R, DelConte A, et al. Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 microg levonorgestrel and 20 microg ethinyl estradiol (Alesse). North American Levonorgestrel Study Group (NALSG). Am J Obstet Gynecol 1999 Nov; 181 (5 Pt 2): 39–44PubMedCrossRef
Metadata
Title
Effects of Oral Contraceptives Containing Ethinylestradiol with Either Drospirenone or Levonorgestrel on Various Parameters Associated with Well-Being in Healthy Women
A Randomized, Single-Blind, Parallel-Group, Multicentre Study
Authors
Sue Kelly
Emyr Davies
Simon Fearns
Carol McKinnon
Dr Rick Carter
Christoph Gerlinger
Andrew Smithers
Publication date
01-05-2010
Publisher
Springer International Publishing
Published in
Clinical Drug Investigation / Issue 5/2010
Print ISSN: 1173-2563
Electronic ISSN: 1179-1918
DOI
https://doi.org/10.2165/11535450-000000000-00000

Other articles of this Issue 5/2010

Clinical Drug Investigation 5/2010 Go to the issue